- Sanofi halts development of troubled immune drug in eczema<figure><div><img src="https://imgproxy.divecdn.com/FBR1IQNmU9Hqatva496Zg2G8JMHsqV0UGsf4LMARqYo/g:nowe:189:144/c:1776:1003/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS80OTY5MDc4Mzc…BioPharma Dive · 3h ago↗ source
- Sanofi’s $1.4B Kymab bet falters again as atopic dermatitis trials scrappedSanofi had hoped the acquisition of Kymab would fill a major hole that will be left as autoimmune juggernaut Dupixent heads toward a patent cliff. Now, another therapy has failed to meet expectations.BioSpace · 4h ago↗ source
- Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotechJennifer Doudna–founded Scribe Therapeutics intends to use the proceeds from the public offering—the first for a gene editing outfit in over two years—to support development of its epigenetic silen…